Actinium Pharma (ATNM) – StreetInsider.com Reports
-
Actinium Pharma (ATNM) Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML
-
Actinium Pharma (ATNM) Reports Iomab-B Phase 3 SIERRA Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients
-
Actinium Pharma (ATNM) Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with Leading FDA Approved Commercial CAR T-Cell Therapy
-
Actinium Pharma (ATNM) Launches Actinium-225 Focused Strategic Initiative
-
Actinium Pharma (ATNM) Reports Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML
-
Actinium Pharma (ATNM) Highlights Improved Survival with Iomab-B
-
Actinium Pharma (ATNM) Files $500M Mixed Shelf
-
Actinium (ATNM) Announces Iomab-B Produces High Response Rates and Significant Improvement in OS in R/R AML Patients with Active Disease Overcoming TP53 Mutation
-
Actinium Pharma (ATNM) PT Lowered to $16 at B.Riley
-
Actinium Pharma (ATNM) Presentations at ASH Highlight the Positive Outcomes for Iomab-B and Actimab-A in Patients with R/R AML
-
Actinium Pharma (ATNM) Appoints Lynn Bodarky as Chief Business Officer
-
Actinium Pharma (ATNM) Announces NIH Grant Extension to Advance Clinical Development of Next-Generation CD45 Targeted Conditioning Agent Iomab-ACT with Memorial Sloan Kettering's CAR-T Cell Therapy
-
Amgen and Biogen 'look attractive' - HSBC
-
HSBC Starts Actinium Pharma (ATNM) at Buy
-
Actinium Pharma (ATNM) PT Lowered to $50 at H.C. Wainwright
-
Actinium Pharma (ATNM) Files $500M Mixed Shelf
-
Actinium Pharma (ATNM) Announces Positive Pivotal Phase 3 SIERRA Trial Results
-
Actinium Pharma (ATNM) to Join Russell 2000 and Russell 3000 Indexes
-
Actinium Pharma (ATNM) Highlights Successful Administration of Targeted Radiotherapy Iomab-B Across Various BMT Centers
-
Actinium Pharma (ATNM) Announces Positive Pivotal Phase 3 SIERRA Trial Results of Iomab-B Showcased to the European Transplant Community in Oral Presentation
-
Actinium Pharma (ATNM) Highlights First-In-Class HER3 Targeted Radiotherapy Data
-
Actinium Pharma (ATNM) Presents Data Demonstrating Actimab-A's Potential
-
Actinium Pharma (ATNM) PT Raised to $27 at Cantor Fitzgerald
-
Actinium Pharma (ATNM) to Discuss Positive Results from the Pivotal Phase 3 SIERRA Trial of Iomab-B
-
William Blair Downgrades Actinium (ATNM) to Market Perform, 'Due to Changing Paradigm, Regulatory Risks, Commercial Headwinds for Lead Asset Iomab-B'
-
Actinium Pharma (ATNM) Reports Positive Full Data Results From Phase 3 SIERRA Trial
-
Actinium Pharma (ATNM) Signs Cooperative Research and Development Agreement with National Cancer Institute
-
Actinium Pharma (ATNM) Announces Research Collaboration with Columbia University to Study Actimab-A in AML Patients Following Transplant of Engineered Hematopoietic Stem Cells Gene Edited to be CD33 N
-
Actinium Pharma (ATNM) Reports Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML
-
Actinium Pharma (ATNM) Appoints Caroline Yarbrough as Chief Commercial Officer
-
Actinium Pharma (ATNM) PT Raised to $53 at H.C. Wainwright
-
Increasing unusual option volume: ATNM MNTV EFX STAA TSP TEN
-
Actinium Pharma (ATNM) PT Raised to $35 at Maxim Group
-
Actinium Pharma (ATNM) PT Raised to $18 at B.Riley
-
Actinium Pharma (ATNM) Reports Positive Top-line Results from Phase 3 SIERRA Trial of Iomab-B
-
Actinium Pharma (ATNM) Appoints Jenny Hsieh as Chief Strategy Officer
-
Actinium Pharma (ATNM) Announces Iomab-B SIERRA Trial Database Lock, Provides Corporate Update
-
Cantor Fitzgerald Starts Actinium Pharma (ATNM) at Overweight
-
B.Riley Starts Actinium Pharma (ATNM) at Buy
-
Actinium Pharma (ATNM) Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in
-
Actinium Pharma (ATNM) Climbs 40% Following Pact with Immedica for Iomab-B
-
Actinium Pharma (ATNM) Enters Commercialization Agreement with Immedica for Iomab-B in in Europe, the Middle East and North Africa
-
Actinium Pharma (ATNM) Reports Potent Anti-Tumor Activity of a HER3 Targeted Radiotherapy
-
Actinium Pharma (ATNM) Reports Preclinical Data Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect
-
Actinium Pharma (ATNM) and AVEO Oncology (AVEO) Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
-
Actinium Pharma (ATNM) and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPĪ± Immunotherapy
-
Actinium Pharma (ATNM) Reports 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML
-
Actinium (ATNM) Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at AS
-
Actinium Pharma (ATNM) Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for Primary Endpoint of the Pivotal Phase 3 SIERRA Tr
-
Actinium Pharma (ATNM) Reports First Data with a CD47 Immunotherapy in Combination with a HER2-Directed Targeted Radiotherapy in Solid Tumors
Back to ATNM Stock Lookup
